Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy
Go back to Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy| Pfizer Inc. (NYSE: PFE) | Delayed: 26.31 -0.31 (1.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.62 | 52 Week High | $37.39 | |||
| Open | $26.39 | 52 Week Low | $28.25 | |||
| Day High | $26.44 | P/E | 15.95 | |||
| Day Low | $26.18 | EPS | $1.65 | |||
| Volume | 32,583,438 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 6,229 | |||||
